Screener
Tarsus Pharmaceuticals, Inc. TARS Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $173.91M+69.4% | $162.05M+107% | $151.67M+128% | $118.7M+147% | $102.66M+152% | ||
| $12.11M+94.2% | $9.4M+80.3% | —— | —— | $6.24M— | ||
| $161.8M+67.8% | $152.66M+109% | —— | —— | $96.42M— | ||
| 93%-0.9pp | 94.2%+0.9pp | —— | —— | 93.9%— | ||
| $31.01M+98.9% | $22.35M+55.1% | $18.04M+6.9% | $16.28M+34.3% | $15.59M+26.6% | ||
| $150.7M+46.3% | $136.43M+60.5% | $130.68M+89.3% | $108.63M+87.6% | $103.01M+75.2% | ||
| $193.82M+55.2% | $168.18M+60.8% | $159.64M+75.8% | $133.23M+81.8% | $124.84M+68.4% | ||
| -$19.91M+10.3% | -$6.12M+76.7% | -$7.98M+67.3% | -$14.53M+42.3% | -$22.18M+33.4% | ||
| -11.4%+10.2pp | -3.8%+29.8pp | -5.3%+31.5pp | -12.2%+40.1pp | -21.6%+60.0pp | ||
| $2.16M-3.8% | $2.13M-3.8% | $2.21M-4.2% | $2.27M-7.2% | $2.24M+6.2% | ||
| $4.07M+121% | $1.51M+29.9% | $1.66M+27.1% | $1.94M+11.6% | $1.84M+15,267% | ||
| —— | —— | -$16.09M+44.3% | -$16.09M+44.3% | -$16.09M+44.3% | ||
| $2.72M— | $2.35M— | —— | —— | $0— | ||
| -$18.55M+8.8% | -$6.97M+72.3% | -$8.37M+63.8% | -$12.59M+46.3% | -$20.34M+38.9% | ||
| -10.7%+9.1pp | -4.3%+27.8pp | -5.5%+29.3pp | -10.6%+38.1pp | -19.8%+61.8pp | ||
| -$0.43+10.4% | -$0.16+75.0% | -$0.19+67.8% | -$0.30+50.8% | -$0.48+45.5% | ||
| -$18.91M+13.2% | -$5.69M+78.0% | -$7.53M+68.6% | -$14.13M+43.2% | -$21.78M+34.2% | ||
| -10.9%+10.3pp | -3.5%+29.5pp | -5%+31.2pp | -11.9%+39.8pp | -21.2%+59.9pp | ||
| -$19.91M+10.3% | -$6.12M+76.7% | -$7.98M+67.3% | -$14.53M+42.3% | -$22.18M+33.4% |
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s revenue?
- Tarsus Pharmaceuticals, Inc. (TARS) generated $606.3M in revenue over the trailing twelve months, up 105.2% year over year.
- Is Tarsus Pharmaceuticals, Inc. profitable?
- Tarsus Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $46.5M over the trailing twelve months, a -7.7% net margin.
- What are Tarsus Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 79.8% and operating margin is -8.0%, with a -7.7% net margin.
- What is Tarsus Pharmaceuticals, Inc.'s earnings per share?
- Tarsus Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.08.
- Where does Tarsus Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
